CTOs on the Move

Regenacy Pharmaceuticals

www.regenacy.com

 
Regenacy Pharmaceuticals is developing a novel, disease-modifying approach to treating peripheral neuropathies that goes beyond pain and symptom management to restore peripheral nerve function.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Regenacy Pharmaceuticals raised $30M on 03/25/2020

Similar Companies

Pharmexa-Epimmune

Pharmexa-Epimmune Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Exagen Diagnostics Inc.

Exagen Diagnostics Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Advanced Solutions

Advanced Solutions designs and manufactures biofabrication systems for next-generation drug discovery, personalized medicine, and regenerative therapeutics.

Quellis Biosciences

Quellis was founded to deliver best-in-class therapies to patients suffering serious rare diseases – and underserved by current treatment options. The Company is based in Boston, and is led by partners from the biotech incubator Viridian LLC in collaboration with team at biotech accelerator Xontogeny LLC, and with funding from the Perceptive Xontogeny Venture Fund. The Quellis team has deep experience in mAb discovery and development, company creation, and private and public biotech investment. Our shared goal is to create meaningful medicines for every disease we target.

Nexstim

Founded in Finland in 2000, Nexstim is the world leader in Navigated Brain Stimulation (NBS) with image-guided Transcranial Magnetic Stimulation (TMS). The company is committed to improving the quality of life of patients. Nexstim has pioneered the technology for brain diagnostics with the Navigated Brain Stimulation (NBS) System as the first and only FDA-cleared and CE-marked navigated TMS (nTMS) device for pre-surgical mapping of the motor and speech cortices. The advanced technology providing navigation to TMS has led NBS to be recognized as the emerging standard for pre-operative direct functional mapping. Nexstim initiated its two year multicenter clinical trial on the therapeutic effects of nTMS for stroke rehabilitation in June 2014 with Navigated Brain Therapy